Price movement over the last 24 hours
Abeona Therapeutics Inc vs Apartment Investment and Management Co — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Apartment Investment and Management Co trades at $2.9 (market cap $422.94M). The key difference: Abeona Therapeutics Inc and Apartment Investment and Management Co are close in size by market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Apartment Investment and Management Co nearer its low. Which is the better fit depends on your goals.
| ABEO | AIV | |
|---|---|---|
Market Cap | $373.32M | $422.94M |
Sector | Health | Real Estate |
52-Week High | $7.23 | $8.76 |
52-Week Low | $4.17 | $2.87 |
Enterprise Value | $228.22M | $669.06M |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
AIV trades at $2.94, down 0.68% on the day, with a bearish technical signal from moving averages. The company reported a net income of $554.01M for 2025, driven by a significant tax benefit, though revenue declined to $138.49M. Analyst consensus is mixed with 1 Buy and 2 Hold ratings. A $1.30 per share liquidating distribution is scheduled for June 2026, reflecting corporate restructuring efforts.
Outlook is cautious due to volatile earnings history and declining revenue, but the high net income margin and planned distribution offer some investor appeal. Key risks include inconsistent operational performance and high leverage, while institutional sentiment remains neutral pending clearer growth catalysts.
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development and Redevelopment
Read more on AIV →